Max Lewandowski

Max Lewandowski

Auto-generated profile, based on publicly available information

Max Lewandowski

Ludwig-Maximilians-Universität München

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2024 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
MSMinh Sai
Minh Sai
EHEmily C. Hank
Emily C. Hank
HTHin-Man Tai
Hin-Man Tai
TKTill Kasch
Till Kasch
MLMax Lewandowski
Max Lewandowski
DMDaniel Merk
Daniel Merk
The neuroprotective transcription factor nuclear receptor-related 1 (Nurr1) has shown great promise as a therapeutic target in Parkinson’s and Alzheimer’s disease as well as multiple sclerosis but high-quality chemical tools for pharmacological target validation of Nurr1 are rare. We have employed the weak Nurr1 modulator amodiaquine (AQ) and AQ-derived fragments as templates to design a new Nurr1 agonist chemotype by scaffold hopping and fragment growing strategies. Systematic structural optimization of this scaffold yielded Nurr1 agonists with nanomolar potency and binding affinity. Comprehensive in vitro profiling revealed efficient cellular target engagement and compliance with the highest probe criteria. In human midbrain organoids bearing a Parkinson-driving LRRK2 mutation, a novel Nurr1 agonist rescued tyrosine hydroxylase expression highlighting the potential of the new Nurr1 modulator chemotype as lead and as a chemical tool for biological studies.

20 February 2025 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
MLMax Lewandowski
Max Lewandowski
RBRomy Busch
Romy Busch
JMJulian A. Marschner
Julian A. Marschner
DMDaniel Merk
Daniel Merk
Nuclear receptors regulate transcription in response to ligand signals and enable the pharmacological control of gene expression. However, many nuclear receptors are still poorly explored and are not accessible to ligand-based target identification studies. In particular, most members of the NR2 family are among the least studied proteins of the class, and apart from the retinoid X receptors (RXR), validated NR2 ligands are very rare. Here, we gathered the NR2 modulators reported in literature for comparative profiling in uniform test systems. Most candidate compounds displayed insufficient on-target activity or selectivity to be used as chemical tools for NR2 receptors underscoring the urgent need for further NR2 ligand development. Nevertheless, a small NR2 modulator set could be assembled for application in a chemogenomic fashion.

7 February 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MEMarkus Egner
Markus Egner
RBRomy Busch
Romy Busch
ÚLÚrsula López-García
Úrsula López-García
MLMax Lewandowski
Max Lewandowski
GHGeorg Höfner
Georg Höfner
DMDaniel Merk
Daniel Merk
The dopamine metabolite 5,6-dihydroxyindole (DHI) has been discovered as a natural Nurr1 ligand with potential biological relevance and is an attractive lead for Nurr1 modulator development but exhibits chemical reactivity and weak potency. We have systematically explored the SAR of 5-chloroindole-6-carboxamide as a DHI mimetic scaffold and identified the first high-affinity (Kd 0.08-0.12 μM) ligands of the DHI binding site of Nurr1. An optimized Nurr1 agonist of this scaffold endowed with favorable physicochemical properties, high selectivity, and low toxicity emerges as a chemical tool to explore the biological impact of Nurr1 activation via the DHI binding site. Treatment of neuronal cells with this compound mediated enhanced expression of Nurr1-regulated neuroprotective genes like brain-derived neurotrophic factor (BDNF), supporting the great potential of Nurr1 activation in neurodegeneration.

23 January 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MMMarko Mitrović
Marko Mitrović
FGFrancesco Aleksy Greco
Francesco Aleksy Greco
YGYiliam Cruz García
Yiliam Cruz García
ALAleksandar Lučić
Aleksandar Lučić
LHLasse Hoffmann
Lasse Hoffmann
SKStefan Knapp
Stefan Knapp
Targeted protein degradation is one of the fastest developing fields in medicinal chemistry and chemical biology. Despite significant development in assay technologies and inhibitor discovery, the development of PROTACs remains a challenging endeavor since rational design approaches remain widely elusive. Our workflow eliminates the rate-limiting step of classic synthesis, namely compound purification, and pairs it with high-throughput, semi-automated plate-based synthesis, and direct cellular assay evaluation. We applied this direct-to-biology approach to four diverse targets, demonstrating the general applicability of this technology. PROTAC synthesis was realized by using the highly efficient copper-catalyzed azide-alkyne cycloaddition reaction. This simplified reaction setup enabled synthesis in the nanomole scale with reaction volumes as low as 5 μL. The high-throughput strategy allows hundreds of PROTACs to be synthesized and evaluated within a few days, facilitating comprehensive assessment of target degradability, rapid hit identification, and selection of the most suitable E3 ligase for degrader development.

18 January 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MLMax Lewandowski
Max Lewandowski
MCMelania Carmina
Melania Carmina
LKLoris Knümann
Loris Knümann
MSMinh Sai
Minh Sai
SWSabine Willems
Sabine Willems
DMDaniel Merk
Daniel Merk

24 July 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FNFelix Nawa
Felix Nawa
AKArthur Kardanov
Arthur Kardanov
TKTill Kasch
Till Kasch
MLMax Lewandowski
Max Lewandowski
TWThomas Wein
Thomas Wein
DMDaniel Merk
Daniel Merk